TB vaccine development: monitoring international patent filings to anticipate access challenges
Maps international patent filings for two late-stage TB vaccine candidates, MTBVAC and M72/AS01E, as well as the QS-21 adjuvant used in M72/AS01E
Sierra Leone
Preparing for Tuberculosis Vaccine M72/AS01E Implementation
This correction relates to the global demand forecast for the potential implementation of the M72/AS01E TB vaccine
Facing up to reality? What to do if M72/AS01E doses are limited
The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a
positive result, could be licensed by 2030. Modelling suggested a large potential impact from
introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is
likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding
the allocation of constrained doses on the potential global impact of M72/AS01E
Cost and Cost Effectiveness of Novel Tuberculosis Vaccines in Low-and Middle-income Countries: A Systematic Review of Modelling Studies
This review addressed the costs and cost-effectiveness of novel tuberculosis (TB) vaccines compared to the current standard of care (BCG) in various settings and for different age groups in LMICs
New Tuberculosis vaccines for people with HIV
Mathematical modelling study assessing how different strategies for vaccinating people with and without HIV could reduce TB cases among people with HIV in high HIV/TB burden countries
The potential health and economic impact of introducing the vaccine candidate VPM1002 to prevent tuberculosis disease in low- and middle-income countries
This study estimates the potential health and economic impact of introducing the TB vaccine candidate VPM1002 in 79 low- and middle- income countries. It models routine vaccination and vaccination campaigns, estimating TB cases and deaths averted and the cost-effectiveness of different introduction scenarios. It provides evidence for decisions about the potential future introduction and scale-up of VPM1002
Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report
A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.
Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.
To aid in prioritizing the development of tuberculosis (TB) vaccines most likely to reach the 2050 TB elimination goal, we estimated the impact and cost-effectiveness of a range of vaccine profiles in low- and middle-income countries.
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study
We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.